Centre for Cancer Biology SA Pathology Molecular Pathology Department Frome Road Adelaide SA 5000 Australia
About me
1. The Royal College of Pathologists of Australasia (RCPA).2. Australian Genomics Health Alliance National Steering Committee (AGHA).3. Genomic Healthcare Alliance (GHA).4. Human Genetics Society of Australasia (HGSA).5. American Society of Hematology (ASH).6.Australasian Leukaemia & Lymphoma Group (ALLG) .7.Healthy Development Adelaide (HDA). 8.Australasian Genomic and Associated Technologies Association - (AMATA) 9. South Australian convenor of the Australian Epigenetic Alliance. 10. South Australian Medical Scientists Association 11. Australian Society of Immunology 12. National Association of Research Fellows (NARF) of NHMRC, Incorporated 13. The American Society of Human Genetics 14. The Human Genetics Society of Australasia 15. Australian Society of Medical Research 16.The Genetics Society of Australia.
About me
Date | Title |
---|---|
09/03/2016 |
BLOOD CANCER GENE DISCOVERY, https://news.cancerresearch/blood-cancer-gene-discovery/ |
03/03/2016 |
World-first SA research discovers genetic link to certain types of blood cancers, http://www.adelaidenow.com.au/lifestyle/health/worldfirst-sa-research-discovers-genetic-link-to-certain-types-of-blood-cancers/news-story/986eb97c612c2d0c9ee2c0b3d1177a14 |
02/03/2016 |
Family Blood Cancer Gene Identified, http://www.unisa.edu.au/Media-Centre/Releases/Family-blood-cancer-gene-identified/#.WKzv1tIrJpg |
07/10/2015 |
Top health researchers become AAHMS Fellows, http://www.unisa.edu.au/Media-Centre/Releases/Top-health-researchers-become-AAHMS-Fellows/#.WKzyrtIrJpg |
01/05/2014 |
Australia is the melanoma capital of the world, http://www.hansoninstitute.sa.gov.au/melanoma/ |
06/09/2011 |
Prof Hamish Scott talks to 891 ABC about the gene discovery, http://www.abc.net.au/news/2011-09-06/prof-hamish-scott-talks-to-891-abc-about-the-gene/2873350 |
About me
Professor Hamish Scott did his PhD (1992) and first post-doc at the Women’s and Children’s Hospital and the University of Adelaide. During these 7 years he led the discovery of genes for 3 rare human diseases. After 11 more years, with the persistence of Professor John Hopwood and others in academia and industry, this resulted in either FDA approved therapy (2003) or clinical trials of novel therapies for these diseases.
In 1995, Hamish moved to the University of Geneva Medical School in Switzerland. His focus was, and remains, the application of genetic and genomic technologies to understand diseases processes to improve diagnoses and treatment. He led international collaborations in identification of human genes causing Down syndrome and rare forms of genetic deafness and autoimmunity (e.g. arthritis and multiple sclerosis). This continues to have profound effects on our understanding of basic biology of Down syndrome, hearing and the immune system and lead to new therapeutic strategies in these and related diseases. This was also the start of his interest in cancer and leukemia as children with Down syndrome have a low incidence of solid tumours and a high incidence of leukemia. This is also when he started to work on familial predisposition to leukemia.
Hamish relocated to the Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne in 2000 as the Inaugural Nossal Leadership Fellow. He was appointed as a National Health and Medical Research Council (NHMRC) senior research fellow in 2001. His laboratory identified 2 additional deafness genes and described the role of a gene in reprogramming the DNA of an “adult” cell from “normal” to become a gamete (sperm or oocyte). He also described a cause of familial predisposition to leukemia.
Since returning to Adelaide in January 2008 he has been Deputy and then Head of the Department of Molecular Pathology at SA Pathology, He is an inaugural member of the Centre for Cancer Biology an Affiliate Professor in both the Schools of Medicine and Molecular and Biomedical Science at the University of Adelaide and an Adjunct Professor in the School of Pharmacy and Medical Sciences in the Division of Health Sciences of the University of South Australia. He is an NHMRC principal research fellow, a Founding Fellow of the Faculty of Science (FFSc) of the Royal College of Pathologists of Australasia (RCPA) and a Fellow of the Australian Academy of Health and Medical Sciences (FAHMS). He recently led the identification of mutations in a gene in rare families and patients that predisposed them to acute myeloid leukemia (AML), infectious diseases and lymphoedema. He has helped develop and introduce new technologies and tests for improved treatment (personalized medicine), in particular CML, and is a Joint Director of the ACRF Cancer Genome Facility established at SA Pathology.
He has led recent international collaborations published in Nat Genet and Blood (x2) on identification of germline mutations in rare families and patients that predispose them to acute myeloid leukemia (AML), infectious diseases, lymphoedema (in GATA2 Embergers syndrome and familial MDS/AML) and diverse hematologic malignancies (in DDX41). This has lead international recognition of the fact that there can be a substantive, sometimes monogenic, predisoposition to haematological malignancies and response to treatments.
He is a Joint Director of the CCB ACRF Cancer Genome Facility established at SA Pathology, the Facilitator of the Genomics, Genetics and Drugable Targets pillar, of the South Australian Comprehensive Cancer Consortium, on the Executive Committee of the South Australian Cancer Research Biobank and the National Steering Committee of the newly NHMRC funded Australian Genomics Health Alliance. In these roles he has been central to introducing introduce new technologies for both somatic and germline genotyping (e.g. using next generation sequencing to SA Pathology at a panel, exome and whole genome level) for improved diagnoses and treatment (personalized medicine) for which his team won an SA Health Award for Excellence.
All disease processes in humans have a genetic component, either inherited or acquired by somatic mutation during cell division. It is important to identify genes and mutations that cause disease, predispose families to diseases, or are acquired during disease progression as these are important diagnostic and prognostic markers. They also provide direct targets and biological pathways for therapeutic intervention.
The Molecular Pathology department is co-located with the ACRF Cancer Genomics Facility, which provides access to powerful cutting edge genetic/genomic technologies including bioinformatics, next-generation sequencing and sample preparation robotics. The Department performs both basic and translational research, which... Read more
Research
Excludes commercial-in-confidence projects.
The missing heritability of rare diseases: discovery to implementation, Medical Research Future Fund, 01/01/2023 - 31/12/2027
Germline mutations in familial haematopoietic malignancies identifies new pan-cancer predisposition genes and may alter clinical decision making, including for known cancer genes, NHMRC - Project Grant, 01/01/2019 - 31/12/2022
Preparing Australia for Genomic Medicine: A proposal by the Australian Genomics Health Alliance. Program 1 A national diagnostic and translational research network, + Flagships/Units., NHMRC Targeted Call for Research into Preparing Australia for the Genomics Revolution in Health Care, 01/01/2016 - 30/06/2021
Program 2: A national data repository: scalable, shared and standardised (Genomic and clinical data linkage). CRE: Preparing Australia for Genomic Medicine: A proposal by the Australian Genomics Heal, NHMRC Targeted Call for Research into Preparing Australia for the Genomics Revolution in Health Care, 21/08/2018 - 30/06/2021
Defining the role of a novel transcriptional enhancer element in regulation of Prox1 expression and endothelial cell identity., NHMRC - Project Grant, 01/01/2018 - 31/12/2020
Germline and Somatic Genetic Variation in Cancer, Cancer Council SA - Beat Cancer Fellowship, 01/01/2018 - 31/12/2020
Genetic autopsy of perinatal death: diagnosis and discovery by genome sequencing, NHMRC - Project Grant, 01/01/2017 - 31/12/2020
Mab immunotherapies for myeloid leukemia patients with germline or somatic RUNX1 mutations., NHMRC - Project Grant, 01/01/2018 - 31/12/2020
Biological characterisation and therapeutic options for high risk, DDX41 mutated, haematological malignancies, Cancer Council SA - Beat Cancer, 01/01/2018 - 31/12/2018
Cancer Discovery Accelerator, Australian Cancer Research Foundation, 01/06/2016 - 31/07/2018
Using familial haematological malignancies and germline variants to identify new haematopoietic and pancancer genes, Cancer Council SA - Beat Cancer, 01/01/2017 - 31/12/2017
Co-operation between GATA2 mutation or expression and RAS signalling in AML, NHMRC - Project Grant, 01/01/2015 - 31/12/2017
Using familia predisposition to Chronic Lymphocytic Leukaemia to follow disease progression, NHMRC - Research Fellowship, 01/01/2014 - 31/12/2017
Cancer Discovery Accelerator, Cancer Council SA - Beat Cancer, 08/06/2016 - 08/06/2017
Defining the role of GATA2 in lymphatic vascular development as a means to understanding how GATA2 mutations predispose to human lymphedema., NHMRC - Project Grant, 01/01/2014 - 31/12/2016
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID, ResearcherID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2016 |
Open access
28
21
1
|
2016 |
Open access
561
537
33
|
2016 |
Open access
7
4
|
2016 |
Open access
14
12
1
|
2016 |
Open access
4
3
1
|
Year | Output |
---|---|
2024 |
Open access
1
|
2024 |
Open access
|
2024 |
Open access
|
2024 |
Open access
|
2024 |
|
2024 |
Open access
1
|
2024 |
Open access
|
2024 |
Open access
|
2023 |
Open access
5
5
7
|
2023 |
Open access
19
20
84
|
2023 |
Open access
|
2023 |
8
2
|
2023 |
2
|
2023 |
Open access
11
9
1
|
2023 |
Open access
18
20
5
|
2023 |
Open access
11
3
|
2023 |
14
12
167
|
2023 |
Open access
18
125
|
2023 |
Open access
1
|
2023 |
Open access
24
26
|
2023 |
Open access
11
12
1
|
2023 |
Open access
3
16
|
2023 |
13
|
2023 |
Open access
6
46
|
2023 |
Open access
2
1
|
2023 |
10
166
|
2022 |
3
3
6
|
2022 |
21
17
184
|
2022 |
Open access
15
15
1
|
2022 |
Open access
8
7
|
2022 |
Open access
5
4
|
2022 |
Open access
8
8
25
|
2022 |
Open access
3
4
3
|
2022 |
8
8
2
|
2021 |
Open access
5
4
1
|
2021 |
Open access
33
30
9
|
2021 |
9
8
|
2021 |
5
5
39
|
2021 |
40
39
12
|
2020 |
Open access
9
9
4
|
2020 |
Open access
97
92
5
|
2020 |
2
2
|
2020 |
Open access
68
66
|
2020 |
Open access
10
12
8
|
2020 |
|
2020 |
Open access
4
5
|
2020 |
Open access
12
12
|
2020 |
Open access
29
28
1
|
2020 |
Open access
3
3
1
|
2020 |
Open access
8
8
|
2019 |
Open access
19
17
53
|
2019 |
Open access
14
13
|
2019 |
12
13
|
2019 |
Open access
101
101
83
|
2019 |
11
9
|
2019 |
Open access
7
7
|
2019 |
3
2
|
2018 |
Open access
50
49
|
2018 |
Open access
34
33
2
|
2018 |
Open access
144
139
9
|
2018 |
Open access
49
46
4
|
2017 |
1
1
|
2017 |
Open access
6
6
3
|
2017 |
76
70
|
2017 |
4
2
|
2017 |
Open access
29
23
|
2017 |
Open access
75
61
|
2017 |
Open access
124
106
|
2017 |
Open access
18
15
|
2017 |
Open access
76
69
|
2017 |
Open access
12
11
4
|
2017 |
Open access
23
21
15
|
2017 |
Open access
85
74
|
2016 |
Open access
28
21
1
|
2016 |
Open access
561
537
33
|
2016 |
Open access
7
4
|
2016 |
Open access
14
12
1
|
2016 |
Open access
4
3
1
|
2016 |
Open access
7
6
|
2016 |
Open access
11
1
|
2016 |
Open access
7
7
|
2015 |
2
10
|
2015 |
9
9
|
2015 |
Open access
14
25
|
2015 |
40
35
1
|
2015 |
Open access
37
31
|
2015 |
Open access
32
26
10
|
2015 |
Open access
175
156
16
|
2015 |
Open access
91
84
|
2015 |
2
2
|
2015 |
2
3
|
2014 |
Open access
60
54
|
2014 |
Open access
97
81
|
2014 |
Open access
36
33
|
2014 |
18
18
|
2014 |
Open access
59
55
|
2014 |
Open access
24
24
|
2014 |
Open access
2
|
2013 |
Open access
27
23
|
2013 |
Open access
19
16
|
2013 |
Open access
78
76
|
2013 |
Open access
39
35
|
2012 |
54
45
|
2012 |
Open access
233
207
|
2012 |
Open access
53
49
|
2012 |
Open access
63
57
|
2012 |
Open access
11
12
|
2012 |
Open access
88
78
|
2011 |
Open access
40
38
|
2011 |
36
33
|
2011 |
Open access
9
8
|
2011 |
Open access
494
448
|
2011 |
Open access
161
148
|
2011 |
31
30
|
2011 |
Open access
84
83
|
2011 |
Open access
52
45
|
2011 |
Open access
34
34
|
2011 |
76
72
|
2011 |
Open access
16
16
|
2010 |
Open access
44
38
|
2010 |
51
50
|
2010 |
13
12
|
2010 |
Open access
8
6
|
2010 |
Open access
6
5
|
2010 |
Open access
51
45
|
2010 |
Open access
17
15
|
2010 |
9
10
|
2009 |
Open access
29
28
|
2009 |
49
42
|
2009 |
Open access
67
64
|
2009 |
Open access
114
|
2009 |
Open access
77
76
|
2009 |
5
5
|
2008 |
Open access
236
|
2008 |
Open access
61
58
|
2008 |
Open access
75
70
|
2008 |
Open access
82
80
|
2008 |
Open access
11
10
|
2008 |
Open access
95
|
2008 |
Open access
75
63
|
1. Genetics and pathologic mechanisms of haematological malignancy (HM = leukaemia and lymphoma) predisposition and progressionOur laboratory focuses on disease gene discovery and confirmation utilizing latest genomic technologies. We have accrued samples from over 90 families with predisposition to HM, which are invaluable resource for the identification of genetic and epigenetic changes leading to these and other cancers. Using a combination of strategies including state-of-the-art whole exome and genome next generation sequencing, we have found additional genes that segregate with diseased individuals in some of these families and/or are mutated in sporadic samples. We continue to hunt for additional genes/mutations in families and sporadic samples. Functional studies on potential and identified genes in vitro, ex vivo and in vivo in mice continue to expose mechanisms for predisposition and progression to HM.
2. Diagnostic implementation of NGS for personalised medicineNext generation sequencing has the power to dramatically increase diagnostic test efficiencies, including pricing, and help in personalised medicine for genetic diseases and cancer. We are implementing NGS sequencing tests including panel sequencing for cancers such as lung, melanoma and colorectal, and whole exome sequencing for genetic diseases such as inherited familial cancers.
3. Genetic autopsy of perinatal death: diagnosis and discovery by Whole Genome Sequencing The causes of perinatal death and genetic termination of pregnancy (GTOP) often cannot be established despite autopsy and extensive investigation, often with long term psychological consequences for families. Establishing a cause of perinatal death or congenital abnormalities relies on post-mortem examination, which includes analysis of tissue samples, x-rays, chromosome studies and DNA-based testing. Despite this, the cause is often not identified. The advent of whole genome sequencing (WGS) has provided a powerful new tool for genetic testing. We are implementing WGS analysis to diagnose "unsolved" perinatal death and GTOP cases, which, together with functional assays, will also provide insights into the genetic mechanisms that underlie them.
Research
All disease processes in humans have a genetic component, either inherited or acquired by somatic mutation during cell division. It is important to identify genes and mutations that cause disease, predispose families to diseases, or are acquired during disease progression as these are important diagnostic and prognostic markers. They also provide direct targets and biological pathways for therapeutic intervention.
The Molecular Pathology department is co-located with the ACRF Cancer Genomics Facility, which provides access to powerful cutting edge genetic/genomic technologies including bioinformatics, next-generation sequencing and sample preparation robotics. The Department performs both basic and translational research, which includes implementing these new technologies into its diagnostic tests for personalized medicine.
External engagement & recognition
Organisation | Country |
---|---|
Adaptive Biotechnologies | UNITED STATES |
Alfred Health | AUSTRALIA |
Auckland City Hospital | NEW ZEALAND |
Auckland District Health Board | NEW ZEALAND |
Austin Hospital | AUSTRALIA |
Australasian Leukaemia and Lymphoma Group | AUSTRALIA |
Australian Genomics Health Alliance | AUSTRALIA |
Australian National University | AUSTRALIA |
Baylor College of Medicine | UNITED STATES |
Boston Children's Hospital | UNITED STATES |
Canberra Hospital | AUSTRALIA |
Cardiff University | UNITED KINGDOM |
Cengiz Gökcek Obstetrics and Children's Hospital | TURKEY |
Central Adelaide Local Health Network Incorporated | AUSTRALIA |
Centre Hospitalier Universitaire Vaudois | SWITZERLAND |
Charite - Medical University of Berlin | GERMANY |
Child Health Research Institute | AUSTRALIA |
Chinese Academy of Sciences | CHINA |
David Geffen School of Medicine at UCLA | UNITED STATES |
de Duve Institute | BELGIUM |
Eastern Health | AUSTRALIA |
Ecole Polytechnique | FRANCE |
Emory University | UNITED STATES |
Erasmus University Rotterdam | NETHERLANDS |
Federal University of Alagoas | BRAZIL |
Flinders Centre for Innovation in Cancer | AUSTRALIA |
Flinders Medical Centre | AUSTRALIA |
Flinders University | AUSTRALIA |
French National Centre for Scientific Research | FRANCE |
Garvan Institute of Medical Research | AUSTRALIA |
German Cancer Research Center | GERMANY |
Griffith University | AUSTRALIA |
Hacettepe University | TURKEY |
Hamamatsu University | JAPAN |
Hannover Medical School | GERMANY |
Hanson Centre for Cancer Research | AUSTRALIA |
Hanson Institute | AUSTRALIA |
Harvard University | UNITED STATES |
Haukeland University Hospital | NORWAY |
Heinrich-Heine University Medical Center | GERMANY |
Helsinki University Hospital | FINLAND |
Hofstra University School of Medicine | UNITED STATES |
Hospital Sant Joan de Deu | SPAIN |
Hpital Necker-Enfants Malades | FRANCE |
Hudson Institute of Medical Research | AUSTRALIA |
Humanitas University | ITALY |
Imago Biosciences | UNITED STATES |
Institut Curie | FRANCE |
Institute of Medical and Veterinary Science | AUSTRALIA |
Institute of Myology | FRANCE |
Istituto Superiore di Sanita | ITALY |
Jarrett St Specialist Centre | AUSTRALIA |
Joslin Diabetes Center | UNITED STATES |
Justus Liebig University Giessen | GERMANY |
Karolinska Institute | SWEDEN |
Karolinska University Hospital | SWEDEN |
Kolling Institute of Medical Research | AUSTRALIA |
La Trobe University | AUSTRALIA |
Lady Cilento Children's Hospital | AUSTRALIA |
Lausanne University Hospital | FRANCE |
Leibniz Institute for Analytical Sciences - ISAS | GERMANY |
Leiden University | NETHERLANDS |
London Health Sciences Centre | CANADA |
Lyell McEwin Hospital | AUSTRALIA |
Macquarie University | AUSTRALIA |
Mater Adult Hospital | AUSTRALIA |
Max-Delbruck-Centrum fur Molekulare Medizin | GERMANY |
Mayo Clinic | UNITED STATES |
Medical University of Innsbruck | AUSTRIA |
Meijo University | JAPAN |
Memorial Sloan Kettering Cancer Centre | UNITED STATES |
Memorial Sloan-Kettering Cancer Center | UNITED STATES |
Mental Health Research Institute | UNITED STATES |
MLL Münchner Leukämielabor GmbH | GERMANY |
Moffitt Cancer Center | UNITED STATES |
Monash University | AUSTRALIA |
Murdoch Childrens Research Institute | AUSTRALIA |
National Cancer Institute | UNITED STATES |
National Human Genome Research Institute | UNITED STATES |
National Institute for Biological Standards and Control | UNITED KINGDOM |
National Institute of Environmental Health Sciences | UNITED STATES |
National Institute of Health and Medical Research | FRANCE |
National Institutes of Health | UNITED STATES |
Northwestern University Feinberg School of Medicine | UNITED STATES |
Novartis Institutes for Biomedical Research | UNITED STATES |
Novartis Pharmaceuticals | UNITED STATES |
NSW Health | AUSTRALIA |
Paul Sabatier University | FRANCE |
Perkin Elmer Pty Ltd | UNITED STATES |
Peter MacCallum Cancer Centre | AUSTRALIA |
Poznan University of Medical Sciences | POLAND |
Princess Maxima Center for Pediatric Oncology | NETHERLANDS |
Princess Máxima Center for Pediatric Oncology | NETHERLANDS |
QIMR Berghofer Medical Research Institute | AUSTRALIA |
Queen Mary University of London | UNITED KINGDOM |
Queensland Institute of Medical Research | AUSTRALIA |
Radboud Institute for Molecular Life Sciences | NETHERLANDS |
Roswell Park Cancer Institute | UNITED STATES |
Royal Adelaide Hospital | AUSTRALIA |
Royal Alexandra Hospital for Children | AUSTRALIA |
Royal Brisbane & Women's Hospital | AUSTRALIA |
Royal Brisbane and Women's Hospital | AUSTRALIA |
Royal Children’sHospital | AUSTRALIA |
Royal Children's Hospital | UNITED KINGDOM |
Royal College of Pathologists of Australasia | AUSTRALIA |
Royal Melbourne Hospital | AUSTRALIA |
Royal North Shore Hospital | AUSTRALIA |
Royal Prince Alfred Hospital | AUSTRALIA |
SA Pathology | AUSTRALIA |
San Diego Institute for Allergy and Immunology | UNITED STATES |
Second Military Medical University | CHINA |
Semmelweis University | HUNGARY |
Sequenom | UNITED STATES |
Shanghai Center for Bioinformation Technology | CHINA |
Shanghai Jiao Tong University | CHINA |
Sir Charles Gardiner Hospital | AUSTRALIA |
South Australian Health and Medical and Research Institute (SAHMRI) | AUSTRALIA |
Southern University Of Science And Technology | CHINA |
St Vincent's Hospital | AUSTRALIA |
St. Jude Children's Research Hospital | UNITED STATES |
Sydney Children’s Hospitals Network | AUSTRALIA |
Sydney Children's Hospital | AUSTRALIA |
Sydney Local Health District | AUSTRALIA |
Tartu University | FINLAND |
Texas Children's Hospital | UNITED STATES |
The Children's Hospital of Philadelphia | UNITED STATES |
The Hospital for Sick Children | CANADA |
The Queen Elizabeth Hospital | AUSTRALIA |
Tokyo Medical University | JAPAN |
Tokyo Metropolitan Children’s Medical Center | JAPAN |
Tokyo Metropolitan Children's Medical Center | JAPAN |
University Hospital for Children and Adolescents | GERMANY |
University Hospital Geneva | SWITZERLAND |
University Libre Bruxelles | BELGIUM |
University Medicine Göttingen | GERMANY |
University of Adelaide | AUSTRALIA |
University of Auckland | NEW ZEALAND |
University of Basel | SWITZERLAND |
University of Belgrade | SERBIA |
University of Beograd | SERBIA |
University of Bergen | NORWAY |
University of Birmingham | UNITED KINGDOM |
University of California | UNITED STATES |
University of California San Francisco | UNITED STATES |
University of Cambridge | UNITED KINGDOM |
University of Chicago | UNITED STATES |
University of Colorado Denver | UNITED STATES |
University of Erlangen-Nuremberg | GERMANY |
University of Exeter | UNITED KINGDOM |
University of Geneva | SWITZERLAND |
University of Glasgow | UNITED KINGDOM |
University of Heidelberg | GERMANY |
University of Helsinki | FINLAND |
University of Lausanne | SWITZERLAND |
University of Lubeck | GERMANY |
University of Manchester | UNITED KINGDOM |
University of Melbourne | AUSTRALIA |
University of Minnesota, Twin Cities | UNITED STATES |
University of Montpellier | FRANCE |
University of Montreal | CANADA |
University of Munich | GERMANY |
University of Nantes | FRANCE |
University of New South Wales | AUSTRALIA |
University of Oxford | UNITED KINGDOM |
University of Paris | FRANCE |
University of Pennsylvania | UNITED STATES |
University of Perugia | ITALY |
University of Pittsburgh | UNITED STATES |
University of Putra | MALAYSIA |
University of Queensland | AUSTRALIA |
University of South Australia | AUSTRALIA |
University of Sydney | AUSTRALIA |
University of Tartu | ESTONIA |
University of Texas | UNITED STATES |
University of Texas MD Anderson Cancer Centre | UNITED STATES |
University of Toronto | CANADA |
University of Toulouse - Jean Jaures | FRANCE |
University of Utah | UNITED STATES |
University of Washington | UNITED STATES |
University of Western Australia | AUSTRALIA |
University ofLeuven | BELGIUM |
Uppsala University | SWEDEN |
Vanderbilt University Medical Centre | UNITED STATES |
Victor Chang Cardiac Research Institute | AUSTRALIA |
Waitemata District Health Board | NEW ZEALAND |
Walter and Eliza Hall Institute of Medical Research | AUSTRALIA |
Walter Eliza Hall Institute of Medical Research | AUSTRALIA |
Warsaw University of Technology | POLAND |
Washington University in St Louis | UNITED STATES |
Weill Cornell Medical College | UNITED STATES |
Weizmann Institute of Science | ISRAEL |
Western University | CANADA |
Women's and Children's Hospital | AUSTRALIA |
External engagement & recognition
Engagement/recognition | Year |
---|---|
Project GrantNational Health and Medical Research Council (NHMRC) |
2016 |
FellowAustralian Academy of Health and Medical Science |
2015 |
Teaching & student supervision
Supervisions from 2010 shown
Thesis title | Student status |
---|---|
109455 - Examining the impact of environmental stressors and mutant microenvironment on disease development in models of inherited predisposition to haematological malignancies | Current |
Understanding how lymphatic vessel identity is programmed during development and disease | Current |
Discovery of novel germline genes in familial haematological malignancies | Completed |
Precision medicine in chronic myeloid leukaemia | Completed |
The genomic autopsy: diagnosis and discovery through exome and genome sequencing | Completed |
Transcriptional control of cellular identity in the lymphatic vasculature | Completed |